Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228015 · ClinicalTrials.gov registry record · Phase 1
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
A Phase 1 study, sponsored by Ikena Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT05228015 is a Phase 1 study that was terminated before completion, run by Ikena Oncology. The registered enrollment target is 67 participants.
The verdict
NCT05228015, a Phase 1 study, was terminated before completion, sponsored by Ikena Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.
Interventions
- DRUG Osimertinib
- DRUG IK-930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2022-01-07 |
| Est. Completion | 2024-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05228015
The ClinicalTrials.gov registry entry for NCT05228015 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ikena Oncology, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Osimertinib is the first listed.
NCT05228015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05228015 about?
NCT05228015 is a clinical study titled "Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors". This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or with...
What is the current status of trial NCT05228015?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2022-01-07. Estimated completion is 2024-09-09.
What interventions are being tested in trial NCT05228015?
The interventions under investigation include: Osimertinib (DRUG), IK-930 (DRUG).
Who is sponsoring clinical trial NCT05228015?
This trial is sponsored by Ikena Oncology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.